Cancer immunotherapy of Wilms tumor: a narrative review.
Yu Lin HeJin Yan LiuRahma Taher AlmgramiYing Zhong FanYi ZhangPublished in: Future oncology (London, England) (2024)
Wilms tumor (WT) is the most common malignant tumor of the urinary system in children. Though the traditional treatment of surgery plus radiotherapy and chemotherapy achieves exciting clinical efficacy, in relapsed and refractory cases, the long-term overall survival rates are poor. Besides, chemotherapy and radiation have serious long-term toxic side effects on children. Cancer immunotherapy is a new tumor therapy that works by activating the body's immune system to allow immune cells to kill tumor cells more efficiently. Currently, cancer immunotherapy has been tested in clinical trials or basic studies in WT. This article reviews the current status of clinical trials and basic research of cancer immunotherapy in WT to promote the application of cancer immunotherapy in WT patients.
Keyphrases
- clinical trial
- young adults
- end stage renal disease
- locally advanced
- newly diagnosed
- early stage
- minimally invasive
- chronic kidney disease
- randomized controlled trial
- signaling pathway
- prognostic factors
- radiation induced
- coronary artery disease
- peritoneal dialysis
- systematic review
- rectal cancer
- hodgkin lymphoma
- coronary artery bypass
- open label
- double blind